The current financial score of Amphastar Pharmaceuticals Inc is 8.72. Its financial status is stable, and its operating efficiency is high. Its latest quarterly revenue reached 183.90M, representing a year-over-year increase of 5.44%, while its net profit experienced a year-over-year increase of 2.20%.
The current valuation score of Amphastar Pharmaceuticals Inc is 8.21. Its current P/E ratio is 13.82, which is 123.31% below the recent high of 30.86 and 46.97% above the recent low of 7.33.
The current earnings forecast score of Amphastar Pharmaceuticals Inc is 5.71. The average price target is 22.50, with a high of 30.00 and a low of 20.00.
The current price momentum score of Amphastar Pharmaceuticals Inc is 4.26. Currently, the stock price is trading between the resistance level at 24.92 and the support level at 21.79, making it suitable for range-bound swing trading.
The current institutional shareholding score of Amphastar Pharmaceuticals Inc is 7.00. The latest institutional shareholding proportion is 79.72%, representing a quarter-over-quarter decrease of 6.44%. The largest institutional shareholder is Chuck Royce, holding a total of 294.76K shares, representing 0.05% of shares outstanding, with 38.50% decrease in holdings.
The current risk assessment score of Amphastar Pharmaceuticals Inc is 6.22. The company's beta value is 0.93. This indicates that the stock tends to underperform the index during upward trending markets but experiences smaller declines during downward trending markets.